Ekso Bionics and Vodafone Receive 2016 HealthTechZone Telehealth Award
April 07 2017 - 9:00AM
Ekso Bionics Holdings, Inc. (NASDAQ:EKSO), a robotic exoskeleton
company, announced today that the company received a 2016
Telehealth Award from HealthTechZone.com, a leading healthcare
technology news source that is a subsidiary of Technology Marketing
Corporation (TMC). The award, which recognizes vendors with
proven success in improving health delivery and management, was
granted to the EksoGT™ exoskeleton connected with Vodafone IoT
technology.
Ekso Bionics has developed the EksoPulse™ technology, which is
an advanced cloud-based platform that uniquely allows physical
therapists (PTs) to personalize patient care.
EksoPulse, which is now incorporated into the EksoGT exoskeletons,
allows PTs to not only capture patient progress during sessions,
but to store the therapeutic data in a shared system, to
synchronize that data with cellular technology in order to track
changes in patient performance, and to then make customized
adjustments to care plans.
“We are honored to receive this award together with our partner,
Vodafone,” shared Thomas Looby, Ekso Bionics’ president and chief
executive officer. “Ekso Bionics is at the forefront of exoskeleton
technology development - not only is the EksoGT the first
exoskeleton approved for stroke and spinal cord injuries above T4,
it is now the only device to offer a truly personalized solution
for patients rehabilitating from these life-changing injuries,”
Looby added.
Vodafone's network and global Internet of Things (IoT) SIM –
embedded in each EksoGT exoskeleton suit – ensures reliable
communications for diagnostics by capturing and sharing patient
data with clinicians. With Vodafone IoT technology, clinicians can
now measure how patients are progressing in real time.
“We are very pleased to be recognized by the HealthTechZone
Telehealth Awards for our collaboration with Ekso Bionics,” said
Ivo Rook, Vodafone’s Group Head of IoT. “Vodafone’s Internet of
Things is enabling all types of medical devices to be used anywhere
in the world, which is directly affecting the care that patients
are receiving. Through our partnership with Ekso Bionics, we are
helping to make a positive impact on stroke and spinal cord injury
rehabilitation.”
“It is my pleasure to recognize the EksoGT, an innovative
solution that earned Ekso Bionics and Vodafone the 2016 Telehealth
Award,” said Rich Tehrani, CEO, TMC. “I look forward to seeing more
innovation from these companies in the future.”
For more information, please visit www.tmcnet.com.
About TMCGlobal buyers rely on TMC’s
content-driven marketplaces to make purchase decisions and navigate
markets. This presents branding, thought leadership and lead
generation opportunities for vendors/sellers.
TMC’s Marketplaces:
- Unique, turnkey Online Communities boost search results,
establish market validation, elevate brands and thought leadership,
while minimizing ad-blocking.
- Custom Lead Programs uncover sales opportunities and build
databases.
- In-Person and Online Events boost brands, enhance thought
leadership and generate leads.
- Publications, Display Advertising and Newsletters bolster brand
reputations.
- Custom Content provides expertly ghost-crafted blogs, press
releases, articles and marketing collateral to help with SEO,
branding, and overall marketing efforts.
- Comprehensive Event and Road Show Management Services help
companies meet potential clients and generate leads
face-to-face.
For more information about TMC and to learn how we can help you
reach your marketing goals, please visit www.tmcnet.com.
About Ekso Bionics®Ekso Bionics is a leading
developer of exoskeleton solutions that amplify human potential by
supporting or enhancing strength, endurance and mobility across
medical, industrial and defense applications. Founded in 2005, the
company continues to build upon its unparalleled expertise to
design some of the most cutting-edge, innovative wearable robots
available on the market. Ekso Bionics is the only exoskeleton
company to offer technologies that range from helping those with
paralysis to stand up and walk, to enhancing human capabilities on
job sites across the globe, to providing research for the
advancement of R&D projects intended to benefit U.S. defense
capabilities. The company is headquartered in the Bay Area and is
listed on the Nasdaq Capital Market under the symbol EKSO. For more
information, visit: www.eksobionics.com.
Forward-Looking StatementsAny statements
contained in this press release that do not describe historical
facts may constitute forward-looking statements. Forward-looking
statements may include, without limitation, statements regarding
(i) the plans and objectives of management for future operations,
including plans or objectives relating to the design, development
and commercialization of human exoskeletons, (ii) estimates or
projection of financial results, financial condition, capital
expenditures, capital structure or other financial items, (iii) the
Company's future financial performance and (iv) the assumptions
underlying or relating to any statement described in points (i),
(ii) or (iii) above. Such forward-looking statements are not meant
to predict or guarantee actual results, performance, events or
circumstances and may not be realized because they are based upon
the Company's current projections, plans, objectives, beliefs,
expectations, estimates and assumptions and are subject to a number
of risks and uncertainties and other influences, many of which the
Company has no control over. Actual results and the timing of
certain events and circumstances may differ materially from those
described by the forward-looking statements as a result of these
risks and uncertainties. Factors that may influence or contribute
to the inaccuracy of the forward-looking statements or cause actual
results to differ materially from expected or desired results may
include, without limitation, the Company's inability to obtain
adequate financing to fund the Company's operations and necessary
to develop or enhance our technology, the significant length of
time and resources associated with the development of the Company's
products, the Company's failure to achieve broad market acceptance
of the Company's products, the failure of our sales and marketing
organization or partners to market our products effectively,
adverse results in future clinical studies of the Company's medical
device products, the failure to obtain or maintain patent
protection for the Company's technology, failure to obtain or
maintain regulatory approval to market the Company's medical
devices, lack of product diversification, existing or increased
competition, and the Company's failure to implement the Company's
business plans or strategies. These and other factors are
identified and described in more detail in the Company's filings
with the SEC. To learn more about Ekso Bionics please visit us at
www.eksobionics.com. The Company does not undertake to update
these forward-looking statements.
Ekso Bionics Media Contact:
Carrie Yamond
917-371-2320
cyamond@lazarpartners.com
Ekso Bionics Investor Contact:
Debbie Kaster
415-937-5403
investors@eksobionics.com
TMC Contact:
Stephanie Thompson, Manager
203-852-6800, ext. 139
sthompson@tmcnet.com
Ekso Bionics (NASDAQ:EKSO)
Historical Stock Chart
From Mar 2024 to Apr 2024
Ekso Bionics (NASDAQ:EKSO)
Historical Stock Chart
From Apr 2023 to Apr 2024